Clearfit
Payments companies reported to CMS as associated with Clearfit. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Clearfit, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Clearfit
These are the largest totals companies reported as associated with Clearfit. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jill Kalman | New York, NY | Cardiovascular Disease | $184,988.36 |
| David Langer | New York, NY | Neurological Surgery | $152,011.22 |
| Christopher Duma | Newport Beach, CA | Neurological Surgery | $114,671.55 |
| Netanel Benshalom | New York, NY | Neurological Surgery | $69,971.30 |
| Erez Nossek | New York, NY | Neurological Surgery | $58,734.44 |
| Zsolt Garami | Houston, TX | General Practice | $42,229.29 |
| Eran Bornstein | New York, NY | Maternal & Fetal Medicine | $37,317.35 |
| Sudhakar Vadivelu | Cincinnati, OH | Neurological Surgery | $34,556.00 |
| Elad Levy | Williamsville, NY | Neurological Surgery | $24,160.76 |
| Amir Dehdashti | Danville, PA | Neurological Surgery | $13,211.90 |
Prescribed Clearfit?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.